Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · AVTX · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
31
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Avalo Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
AVTX insider buying and selling by quarter
AVTX insider selling · AVTX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · AVTX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
AVTX executive sell shares · AVTX board member insider trading · AVTX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 28, 2026 | Doyle Mittie Chief Medical Officer | Option | 679 | $5K | Form 4 |
| May 28, 2026 | Doyle Mittie Chief Medical Officer | Sale | 679 | $11K | Form 4 |
| May 21, 2026 | Riley Jennifer Chief Strategy Officer | Award | 34,200 | — | Form 4 |
| May 21, 2026 | Sullivan Christopher Ryan CFO | Award | 39,900 | — | Form 4 |
| May 21, 2026 | VARKI PAUL Chief Legal Officer | Award | 24,300 | — | Form 4 |
| May 21, 2026 | Doyle Mittie Chief Medical Officer | Award | 43,500 | — | Form 4 |
| May 21, 2026 | NEIL GARRY ARTHUR CEO · Director | Award | 100,200 | — | Form 4 |
| May 15, 2026 | Doyle Mittie Chief Medical Officer | Option | 3,000 | $38K | Form 4 |
| May 15, 2026 | Doyle Mittie Chief Medical Officer | Sale | 3,000 | $56K | Form 4 |
| May 7, 2026 | Sullivan Christopher Ryan CFO | Option | 18,606 | $184K | Form 4 |
| May 7, 2026 | Sullivan Christopher Ryan CFO | Sale | 18,606 | $449K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Option | 12,563 | $101K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Option | 62,500 | $839K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Sale | 37,375 | $707K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Sale | 5,196 | $103K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Sale | 22,839 | $485K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Sale | 9,253 | $210K | Form 4 |
| May 6, 2026 | VARKI PAUL Chief Legal Officer | Sale | 400 | $9K | Form 4 |
| May 6, 2026 | Sullivan Christopher Ryan CFO | Option | 47,000 | $378K | Form 4 |
| May 6, 2026 | Sullivan Christopher Ryan CFO | Sale | 13,834 | $257K | Form 4 |
| May 6, 2026 | Sullivan Christopher Ryan CFO | Sale | 12,347 | $238K | Form 4 |
| May 6, 2026 | Sullivan Christopher Ryan CFO | Sale | 2,700 | $56K | Form 4 |
| May 6, 2026 | Sullivan Christopher Ryan CFO | Sale | 9,219 | $197K | Form 4 |
| May 6, 2026 | Sullivan Christopher Ryan CFO | Sale | 8,900 | $201K | Form 4 |
| May 6, 2026 | Doyle Mittie Chief Medical Officer | Option | 28,650 | $230K | Form 4 |
Doyle Mittie
Chief Medical Officer
Date
May 15
Shares
3,000
Price
$12.65
Value
$38K
Doyle Mittie
Chief Medical Officer
Date
May 15
Shares
3,000
Price
$18.76
Value
$56K
Doyle Mittie
Chief Medical Officer
Date
May 6
Shares
28,650
Price
$8.04
Value
$230K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About AVTX insider trading
AVTX insider trades
Avalo Therapeutics, Inc. (AVTX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Doyle Mittie (Chief Medical Officer), Sullivan Christopher Ryan (CFO), VARKI PAUL (Chief Legal Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. AVTX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Avalo Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
AVTX insider trading · 5 questionsThe insiders of Avalo Therapeutics, Inc. (AVTX) include executives and directors such as Doyle Mittie (Chief Medical Officer), Sullivan Christopher Ryan (CFO), VARKI PAUL (Chief Legal Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026